TCF4 loss-of-function leads to ectopicoverexpression of Scn10a, and the pharmacological inhibitionof NaV1.8 in murine models of PTHS is effective for the restorationof several physiological functions and behavior (Ekinset al., 2020; Cleary et al., 2021; Martinowich et al., 2022).Specifically, S. Ekins and colleagues used Nicardepine, a drugapproved by the Food and Drug Administration (FDA) andused in cardiology, as a NaV1.8 inhibitor (Ekins et al., 2020).Other selective NaV1.8 inhibitors have also been proven safefor humans in clinical trials (Hijma et al., 2021, 2022). Here, TCF4 is linked to Pitt-Hopkins syndrome.